Concepedia

Roberta Hanna

RH

Statistics

Publications

6

Citations

650

H-Index

6

Active since

1994

Affiliations

Research & Development Corporation(Current)

Amgen (United States)

Roberta Hanna is an author at Research & Development Corporation specializing in immunology, life sciences, and immunotherapy.

Publications per year

1994–2009

6

Publications

6

Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis.

Larry W. Moreland, G Margolies, Heck Lw et al. · PubMed · 1996 · 217 citations

, , +16

The Soluble Form of IL-1 Receptor Accessory Protein Enhances the Ability of Soluble Type II IL-1 Receptor to Inhibit IL-1 Action

Dirk E. Smith, Roberta Hanna, Della Friend et al. · Immunity · 2003 · 183 citations · Full text

, , +15

The Pharmacokinetics of Etanercept in Healthy Volunteers

Joan Korth‐Bradley, Abbe Rubin, Roberta Hanna et al. · Annals of Pharmacotherapy · 2000 · 155 citations

, , +13

Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor.

Michael F. Mullarkey, K M Leiferman, Margot S. Peters et al. · The Journal of Immunology · 1994 · 63 citations

, , +17

A comparison of effects on reproduction and neonatal development in cynomolgus monkeys given human soluble IL-4R and mice given murine soluble IL-4R

Linda L. Carlock, Laine A. Cowan, Satoru Oneda et al. · Regulatory Toxicology and Pharmacology · 2009 · 18 citations

, , +16

1–5 of 6